Ramesh Potla
FDA investigator
Appears on 2 documents from 2019 to 2020, mostly at sites in China. Most often cites general requirements (21 CFR 211.160).
- 2
- Documents on file
- 4.0
- Observations per 483
- 2019
- First seen
- 2020
- Most recent
What they cite most
From 8 observations- 21 CFR 211.160General requirements2
- 21 CFR 211.170Reserve samples2
- 21 CFR 211.180General requirements2
- 21 CFR 211.22Responsibilities of quality control unit2
Activity by year
2019: 1, 2020: 1
Where
China 2
Often inspects with
Is Ramesh Potla coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2020-04-16 | 483 Wuxi Biologics Co LtdApr 16, 2020 · Wuxi, China | Wuxi, China | 4 | |
| 2019-04-16 | 483 WuXi Biologics Co., Ltd.Apr 16, 2019 · Wuxi, China | Wuxi, China | 4 |
About this profile
What does Ramesh Potla inspect?
Ramesh Potla appears on 2 documents on file covering 1 site, mostly in China.
What do they cite most often?
21 CFR 211.160 (general requirements), followed by 21 CFR 211.170 and 21 CFR 211.180.
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Ramesh Potla is dated Apr 16, 2020.